The intervention being tested is HyBryte, a gel containing 0.25% hypericin, applied twice weekly for 18 weeks. It is designed to be activated by visible light to treat CTCL. A placebo gel is used as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback